secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001104659-23-128988
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma receives FDA refusal to file for etripamil NDA for PSVT
------------------------------------------------------------------------

- FDA issued Refusal to File letter for etripamil NDA submitted October 2023.
- FDA cited insufficient completeness, requested clarification on adverse event timing in Phase 3.
- FDA did not express concerns about nature or severity of adverse events.
- Milestone will seek meeting with FDA to address issues and agree on path forward.
- Etripamil is a self-administered nasal spray for paroxysmal supraventricular tachycardia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923128988/0001104659-23-128988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923128988/tm2333688d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-128988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer